
Thirty-one patients with focal chondral lesions of the knee underwent arthroscopic treatment with MaioRegen Chondro+. Over a minimum follow-up period of 2 years, the International Knee Documentation Committee (IKDC) Questionnaire and the Tegner Activity Scale were used for evaluation. Significant improvements were noted in IKDC scores at 6, 12, and 24 months post-treatment, with corresponding enhancements in Tegner scores by 12 months. Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) scores also showed a notable increase. These positive outcomes were consistent across various demographic and lesion-related factors. Notably, the clinical benefits persisted in patients followed up for 3 years. The study concludes that MaioRegen Chondro+ is a safe and productive treatment option for knee chondral lesions, sustaining clinical improvement for at least 2 years.
Like
Save
Share